Do analysts prefer XBIT or LYEL?

Lyell Immunopharma has a consensus price target of $43.00, suggesting a potential upside of 225.26%. Given Lyell Immunopharma's stronger consensus rating and higher possible upside, analysts plainly believe Lyell Immunopharma is more favorable than XBiotech. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score XBiotech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Lyell Immunopharma 1 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.71

Do analysts rate TENX or XBIT?

Tenax Therapeutics presently has a consensus target price of $29.67, suggesting a potential upside of 181.20%. Given Tenax Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Tenax Therapeutics is more favorable than XBiotech. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tenax Therapeutics 1 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.83 XBiotech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable earnings & valuation, TENX or XBIT?

Tenax Therapeutics is trading at a lower price-to-earnings ratio than XBiotech, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Tenax Therapeutics N/A N/A -$52.60M -$1.40 N/A XBiotech N/A N/A -$45.54M -$1.32 N/A

Is TENX or XBIT more profitable?

XBiotech's return on equity of -26.10% beat Tenax Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Tenax Therapeutics N/A -56.32% -53.12% XBiotech N/A -26.10% -25.06%

Do analysts prefer XBIT or ELDN?

Eledon Pharmaceuticals has a consensus price target of $9.67, suggesting a potential upside of 179.38%. Given Eledon Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Eledon Pharmaceuticals is more favorable than XBiotech. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score XBiotech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Eledon Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.40

Which has better valuation and earnings, XBIT or ELDN?

Eledon Pharmaceuticals is trading at a lower price-to-earnings ratio than XBiotech, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio XBiotech N/A N/A -$45.54M -$1.32 N/A Eledon Pharmaceuticals N/A N/A -$45.62M -$0.77 N/A

Is XBIT or ELDN more profitable?

XBiotech's return on equity of -26.10% beat Eledon Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets XBiotech N/A -26.10% -25.06% Eledon Pharmaceuticals N/A -116.97% -41.91%

Do analysts rate NLTX or XBIT?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Neoleukin Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 XBiotech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable valuation and earnings, NLTX or XBIT?

Neoleukin Therapeutics is trading at a lower price-to-earnings ratio than XBiotech, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Neoleukin Therapeutics N/A N/A -$57.56M -$3.11 N/A XBiotech N/A N/A -$45.54M -$1.32 N/A

Is NLTX or XBIT more profitable?

XBiotech's return on equity of -26.10% beat Neoleukin Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Neoleukin Therapeutics N/A -37.22% -30.91% XBiotech N/A -26.10% -25.06%

XBiotech (XBIT) Competitors

$2.35 -0.02 (-0.84%)

Closing price 04:00 PM Eastern

Extended Trading

$2.37 +0.02 (+1.02%)

As of 04:15 PM Eastern

Compare

XBIT vs. LYEL, BCYC, TENX, ELDN, and NLTX

Should you buy XBiotech stock or one of its competitors? MarketBeat compares XBiotech with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with XBiotech include Lyell Immunopharma (LYEL), Bicycle Therapeutics (BCYC), Tenax Therapeutics (TENX), Eledon Pharmaceuticals (ELDN), and Neoleukin Therapeutics (NLTX). These companies are all part of the "pharmaceutical products" industry.

How does XBiotech compare to Lyell Immunopharma?

XBiotech (NASDAQ:XBIT) and Lyell Immunopharma (NASDAQ:LYEL) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, risk, earnings, dividends, institutional ownership, media sentiment, profitability and analyst recommendations.

XBiotech has a net margin of 0.00% compared to Lyell Immunopharma's net margin of -794,858.12%. XBiotech's return on equity of -26.10% beat Lyell Immunopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
XBiotech	N/A	-26.10%	-25.06%
Lyell Immunopharma	-794,858.12%	-85.71%	-66.41%

55.7% of XBiotech shares are owned by institutional investors. Comparatively, 66.1% of Lyell Immunopharma shares are owned by institutional investors. 30.8% of XBiotech shares are owned by company insiders. Comparatively, 6.2% of Lyell Immunopharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

XBiotech has a beta of 0.85, suggesting that its share price is 15% less volatile than the broader market. Comparatively, Lyell Immunopharma has a beta of -0.09, suggesting that its share price is 109% less volatile than the broader market.

Lyell Immunopharma has a consensus price target of $43.00, suggesting a potential upside of 225.26%. Given Lyell Immunopharma's stronger consensus rating and higher possible upside, analysts plainly believe Lyell Immunopharma is more favorable than XBiotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
XBiotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Lyell Immunopharma	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71

XBiotech has higher earnings, but lower revenue than Lyell Immunopharma. XBiotech is trading at a lower price-to-earnings ratio than Lyell Immunopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
XBiotech	N/A	N/A	-$45.54M	-$1.32	N/A
Lyell Immunopharma	$40K	7,710.57	-$274.45M	-$13.80	N/A

In the previous week, Lyell Immunopharma had 8 more articles in the media than XBiotech. MarketBeat recorded 9 mentions for Lyell Immunopharma and 1 mentions for XBiotech. XBiotech's average media sentiment score of 1.87 beat Lyell Immunopharma's score of 0.46 indicating that XBiotech is being referred to more favorably in the media.

Company	Overall Sentiment
XBiotech	Very Positive
Lyell Immunopharma	Neutral

Summary

XBiotech and Lyell Immunopharma tied by winning 8 of the 16 factors compared between the two stocks.

How does XBiotech compare to Bicycle Therapeutics?

Bicycle Therapeutics (NASDAQ:BCYC) and XBiotech (NASDAQ:XBIT) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, risk, media sentiment, earnings, institutional ownership, valuation, dividends and profitability.

86.2% of Bicycle Therapeutics shares are held by institutional investors. Comparatively, 55.7% of XBiotech shares are held by institutional investors. 22.9% of Bicycle Therapeutics shares are held by company insiders. Comparatively, 30.8% of XBiotech shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

XBiotech has lower revenue, but higher earnings than Bicycle Therapeutics. XBiotech is trading at a lower price-to-earnings ratio than Bicycle Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bicycle Therapeutics	$72.86M	3.86	-$218.96M	-$3.15	N/A
XBiotech	N/A	N/A	-$45.54M	-$1.32	N/A

In the previous week, Bicycle Therapeutics had 1 more articles in the media than XBiotech. MarketBeat recorded 2 mentions for Bicycle Therapeutics and 1 mentions for XBiotech. XBiotech's average media sentiment score of 1.87 beat Bicycle Therapeutics' score of 0.93 indicating that XBiotech is being referred to more favorably in the news media.

Company	Overall Sentiment
Bicycle Therapeutics	Positive
XBiotech	Very Positive

Bicycle Therapeutics has a beta of 1.54, suggesting that its stock price is 54% more volatile than the broader market. Comparatively, XBiotech has a beta of 0.85, suggesting that its stock price is 15% less volatile than the broader market.

XBiotech has a net margin of 0.00% compared to Bicycle Therapeutics' net margin of -344.95%. XBiotech's return on equity of -26.10% beat Bicycle Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bicycle Therapeutics	-344.95%	-35.74%	-29.54%
XBiotech	N/A	-26.10%	-25.06%

Bicycle Therapeutics currently has a consensus price target of $14.00, suggesting a potential upside of 247.39%. Given Bicycle Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Bicycle Therapeutics is more favorable than XBiotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bicycle Therapeutics	1 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.44
XBiotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Bicycle Therapeutics beats XBiotech on 8 of the 15 factors compared between the two stocks.

How does XBiotech compare to Tenax Therapeutics?

Tenax Therapeutics (NASDAQ:TENX) and XBiotech (NASDAQ:XBIT) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, risk, dividends, institutional ownership, earnings, profitability, valuation and media sentiment.

Tenax Therapeutics is trading at a lower price-to-earnings ratio than XBiotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tenax Therapeutics	N/A	N/A	-$52.60M	-$1.40	N/A
XBiotech	N/A	N/A	-$45.54M	-$1.32	N/A

Tenax Therapeutics presently has a consensus target price of $29.67, suggesting a potential upside of 181.20%. Given Tenax Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Tenax Therapeutics is more favorable than XBiotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tenax Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
XBiotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Tenax Therapeutics had 1 more articles in the media than XBiotech. MarketBeat recorded 2 mentions for Tenax Therapeutics and 1 mentions for XBiotech. XBiotech's average media sentiment score of 1.87 beat Tenax Therapeutics' score of 0.93 indicating that XBiotech is being referred to more favorably in the news media.

Company	Overall Sentiment
Tenax Therapeutics	Positive
XBiotech	Very Positive

Tenax Therapeutics has a beta of 0.98, suggesting that its stock price is 2% less volatile than the broader market. Comparatively, XBiotech has a beta of 0.85, suggesting that its stock price is 15% less volatile than the broader market.

1.7% of Tenax Therapeutics shares are held by institutional investors. Comparatively, 55.7% of XBiotech shares are held by institutional investors. 3.1% of Tenax Therapeutics shares are held by company insiders. Comparatively, 30.8% of XBiotech shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

XBiotech's return on equity of -26.10% beat Tenax Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tenax Therapeutics	N/A	-56.32%	-53.12%
XBiotech	N/A	-26.10%	-25.06%

Summary

XBiotech beats Tenax Therapeutics on 8 of the 14 factors compared between the two stocks.

How does XBiotech compare to Eledon Pharmaceuticals?

XBiotech (NASDAQ:XBIT) and Eledon Pharmaceuticals (NASDAQ:ELDN) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, valuation, institutional ownership, dividends, media sentiment and earnings.

XBiotech's return on equity of -26.10% beat Eledon Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
XBiotech	N/A	-26.10%	-25.06%
Eledon Pharmaceuticals	N/A	-116.97%	-41.91%

Eledon Pharmaceuticals is trading at a lower price-to-earnings ratio than XBiotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
XBiotech	N/A	N/A	-$45.54M	-$1.32	N/A
Eledon Pharmaceuticals	N/A	N/A	-$45.62M	-$0.77	N/A

Eledon Pharmaceuticals has a consensus price target of $9.67, suggesting a potential upside of 179.38%. Given Eledon Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Eledon Pharmaceuticals is more favorable than XBiotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
XBiotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Eledon Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

55.7% of XBiotech shares are owned by institutional investors. Comparatively, 56.8% of Eledon Pharmaceuticals shares are owned by institutional investors. 30.8% of XBiotech shares are owned by insiders. Comparatively, 12.3% of Eledon Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, Eledon Pharmaceuticals had 5 more articles in the media than XBiotech. MarketBeat recorded 6 mentions for Eledon Pharmaceuticals and 1 mentions for XBiotech. XBiotech's average media sentiment score of 1.87 beat Eledon Pharmaceuticals' score of 0.56 indicating that XBiotech is being referred to more favorably in the media.

Company	Overall Sentiment
XBiotech	Very Positive
Eledon Pharmaceuticals	Positive

XBiotech has a beta of 0.85, suggesting that its stock price is 15% less volatile than the broader market. Comparatively, Eledon Pharmaceuticals has a beta of 0.94, suggesting that its stock price is 6% less volatile than the broader market.

Summary

Eledon Pharmaceuticals beats XBiotech on 7 of the 13 factors compared between the two stocks.

How does XBiotech compare to Neoleukin Therapeutics?

Neoleukin Therapeutics (NASDAQ:NLTX) and XBiotech (NASDAQ:XBIT) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, risk, earnings, media sentiment, dividends, valuation and profitability.

Neoleukin Therapeutics is trading at a lower price-to-earnings ratio than XBiotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neoleukin Therapeutics	N/A	N/A	-$57.56M	-$3.11	N/A
XBiotech	N/A	N/A	-$45.54M	-$1.32	N/A

XBiotech's return on equity of -26.10% beat Neoleukin Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neoleukin Therapeutics	N/A	-37.22%	-30.91%
XBiotech	N/A	-26.10%	-25.06%

52.4% of Neoleukin Therapeutics shares are held by institutional investors. Comparatively, 55.7% of XBiotech shares are held by institutional investors. 1.6% of Neoleukin Therapeutics shares are held by insiders. Comparatively, 30.8% of XBiotech shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neoleukin Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
XBiotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, XBiotech had 1 more articles in the media than Neoleukin Therapeutics. MarketBeat recorded 1 mentions for XBiotech and 0 mentions for Neoleukin Therapeutics. XBiotech's average media sentiment score of 1.87 beat Neoleukin Therapeutics' score of 0.00 indicating that XBiotech is being referred to more favorably in the news media.

Company	Overall Sentiment
Neoleukin Therapeutics	Neutral
XBiotech	Very Positive

Neoleukin Therapeutics has a beta of 1.11, indicating that its stock price is 11% more volatile than the broader market. Comparatively, XBiotech has a beta of 0.85, indicating that its stock price is 15% less volatile than the broader market.

Summary

XBiotech beats Neoleukin Therapeutics on 10 of the 11 factors compared between the two stocks.

Get XBiotech News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding XBIT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

XBIT vs. The Competition

Export

Metric	XBiotech	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$72.26M	$3.34B	$6.50B	$11.95B
Dividend Yield	N/A	2.31%	2.67%	5.61%
P/E Ratio	-1.78	10.45	20.85	21.87
Price / Sales	N/A	290.84	500.87	105.21
Price / Cash	N/A	120.20	43.05	54.72
Price / Book	0.51	8.00	10.43	6.70
Net Income	-$45.54M	$23.89M	$3.56B	$337.26M
7 Day Performance	-1.67%	-3.49%	-1.39%	-1.41%
1 Month Performance	-4.47%	1.03%	0.86%	1.15%
1 Year Performance	-19.24%	34.39%	19.42%	22.61%

XBiotech Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
XBIT XBiotech	1.0272 of 5 stars	$2.35 -0.8%	N/A	-19.4%	$72.26M	N/A	N/A	100
LYEL Lyell Immunopharma	2.6537 of 5 stars	$12.70 +3.2%	$43.00 +238.6%	+1.8%	$287.24M	$40K	N/A	270	News Coverage Analyst Forecast
BCYC Bicycle Therapeutics	3.5354 of 5 stars	$4.17 +1.5%	$14.00 +235.7%	-51.2%	$286.92M	$72.86M	N/A	240	High Trading Volume
TENX Tenax Therapeutics	3.3147 of 5 stars	$10.73 +1.8%	$29.67 +176.5%	+83.1%	$279.58M	N/A	N/A	9	High Trading Volume
ELDN Eledon Pharmaceuticals	1.8494 of 5 stars	$3.55 -0.8%	$9.67 +172.3%	+18.7%	$276.33M	N/A	N/A	10	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:XBIT) was last updated on 6/10/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

XBiotech (XBIT) Competitors

XBIT vs. LYEL, BCYC, TENX, ELDN, and NLTX

How does XBiotech compare to Lyell Immunopharma?

Summary

How does XBiotech compare to Bicycle Therapeutics?

Summary

How does XBiotech compare to Tenax Therapeutics?

Summary

How does XBiotech compare to Eledon Pharmaceuticals?

Summary

How does XBiotech compare to Neoleukin Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

XBIT vs. The Competition

XBiotech Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

XBiotech (XBIT) Competitors

XBIT vs. LYEL, BCYC, TENX, ELDN, and NLTX

How does XBiotech compare to Lyell Immunopharma?

Is XBIT or LYEL more profitable?

Do institutionals and insiders hold more shares of XBIT or LYEL?

Which has more risk & volatility, XBIT or LYEL?

Do analysts prefer XBIT or LYEL?

Which has better valuation & earnings, XBIT or LYEL?

Does the media prefer XBIT or LYEL?

Summary

How does XBiotech compare to Bicycle Therapeutics?

Do insiders & institutionals hold more shares of BCYC or XBIT?

Which has higher valuation and earnings, BCYC or XBIT?

Does the media refer more to BCYC or XBIT?

Which has more volatility and risk, BCYC or XBIT?

Is BCYC or XBIT more profitable?

Do analysts rate BCYC or XBIT?

Summary

How does XBiotech compare to Tenax Therapeutics?

Which has preferable earnings & valuation, TENX or XBIT?

Do analysts rate TENX or XBIT?

Does the media prefer TENX or XBIT?

Which has more risk & volatility, TENX or XBIT?

Do insiders and institutionals hold more shares of TENX or XBIT?

Is TENX or XBIT more profitable?

Summary

How does XBiotech compare to Eledon Pharmaceuticals?

Is XBIT or ELDN more profitable?

Which has better valuation and earnings, XBIT or ELDN?

Do analysts prefer XBIT or ELDN?

Do institutionals & insiders hold more shares of XBIT or ELDN?

Does the media prefer XBIT or ELDN?

Which has more volatility and risk, XBIT or ELDN?

Summary

How does XBiotech compare to Neoleukin Therapeutics?

Which has preferable valuation and earnings, NLTX or XBIT?

Is NLTX or XBIT more profitable?

Do insiders & institutionals believe in NLTX or XBIT?

Do analysts rate NLTX or XBIT?

Does the media favor NLTX or XBIT?

Which has more risk and volatility, NLTX or XBIT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

XBIT vs. The Competition

XBiotech Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools